EKTAF: AI 评分 47/100 — AI 分析 (4月 2026)

Elekta AB (publ) is a medical technology company specializing in clinical solutions for cancer and brain disorders. The company operates globally, offering a range of radiation therapy and neurosurgery products, including linear accelerators, stereotactic radiosurgery systems, and brachytherapy solutions.

Key Facts: AI Score: 47/100 Sector: Healthcare

公司概况

概要：

Elekta AB (publ) is a Swedish medical technology firm providing radiation therapy and neurosurgery solutions globally. Its diverse product portfolio, including linear accelerators and Gamma Knife systems, addresses cancer and brain disorders. With a focus on innovation and comprehensive care services, Elekta serves a critical role in the medical device industry.

EKTAF是做什么的？

Elekta AB (publ), founded in 1972 and headquartered in Stockholm, Sweden, is a medical technology company dedicated to providing innovative clinical solutions for treating cancer and brain disorders. The company operates across the Americas, Europe, the Middle East, Africa, and the Asia Pacific regions. Elekta's core offerings include linear accelerators and radiation therapy products designed to deliver precise and effective treatment. Key products include Elekta Unity, which integrates MR imaging for anatomy-specific targeting; Elekta Evo, enabling adaptive radiation therapy; Elekta Versa HD, a solution for brain metastases; Elekta Harmony; and Elekta Infinity, catering to a wide range of radiotherapy needs. In addition to linear accelerators, Elekta provides stereotactic radiosurgery products such as the Elekta Esprit Gamma Knife system and Leksell GammaPlan treatment planning software. The company also offers brachytherapy solutions, including Elekta Studio for image-guided brachytherapy and Elekta Flexitron afterloader for precise workflow execution. Elekta's product portfolio extends to neurosurgery with the Leksell Vantage Stereotactic System and personalized cancer care solutions like Elekta Kaiku. Furthermore, the company provides veterinary radiation therapy solutions, expanding its reach beyond human medicine. Elekta complements its product offerings with comprehensive support services under the Elekta Care umbrella, including training, a self-help center, and predictive maintenance through Elekta Intellimax. This holistic approach positions Elekta as a key player in the global medical technology market, committed to advancing cancer and brain disorder treatments.

EKTAF的投资论点是什么？

Elekta AB (publ) presents a mixed investment case. While the company operates in a growing market for cancer and brain disorder treatments, its negative profit margin of -0.2% and ROE of -0.4% raise concerns about profitability. The company's high debt-to-equity ratio of 90.91 may limit financial flexibility. Growth catalysts include the expansion of its Elekta Unity and Elekta Harmony product lines, as well as the increasing demand for advanced radiation therapy solutions. However, investors should closely monitor the company's ability to improve profitability and manage its debt levels. The company's beta of 1.09 indicates market correlation.

EKTAF在哪个行业运营？

Elekta AB (publ) operates within the medical device industry, specifically focusing on radiation therapy and neurosurgery solutions. The industry is driven by increasing cancer prevalence, technological advancements, and an aging global population. Competition includes companies like Varian Medical Systems (VAR), Accuray Incorporated (ARAY), and Siemens Healthineers (SIEGY), each vying for market share with innovative treatment solutions. The market for radiation therapy equipment is expected to grow, driven by demand for precision and minimally invasive treatments.

Medical Devices

Healthcare

EKTAF有哪些增长机遇？

Expansion of Elekta Unity: Elekta Unity, with its anatomy-specific MR imaging, represents a significant growth opportunity. The global MRI market is projected to reach $7.3 billion by 2027, driven by advancements in imaging technology and increasing demand for diagnostic accuracy. Elekta can leverage this trend by expanding the adoption of Elekta Unity in cancer centers worldwide, offering enhanced treatment precision and personalized care. Timeline: Ongoing.
Adoption of Elekta Harmony: Elekta Harmony is designed to address a wide range of radiotherapy needs, from simple to complex cases. The global radiotherapy market is expected to reach $8.7 billion by 2028, fueled by the rising incidence of cancer and advancements in treatment techniques. By promoting Elekta Harmony as a versatile and efficient solution, Elekta can capture a larger share of this expanding market. Timeline: Ongoing.
Growth in Stereotactic Radiosurgery: Elekta's stereotactic radiosurgery products, including the Elekta Esprit Gamma Knife system, offer a non-invasive alternative for treating brain disorders. The global stereotactic radiosurgery market is projected to grow, driven by the increasing demand for minimally invasive procedures and technological advancements. Elekta can capitalize on this trend by expanding the availability of its Gamma Knife systems and treatment planning software. Timeline: Ongoing.
Brachytherapy Solutions: Elekta's brachytherapy products, such as Elekta Studio and Elekta Flexitron, provide precise and targeted radiation therapy. The global brachytherapy market is expected to grow, driven by the increasing demand for localized cancer treatments and technological advancements. Elekta can strengthen its position by promoting its brachytherapy solutions as an effective and efficient treatment option. Timeline: Ongoing.
Elekta Care Services: Elekta Care support services, including training, a self-help center, and predictive maintenance, offer a recurring revenue stream and enhance customer loyalty. The global healthcare support services market is expected to grow, driven by the increasing demand for comprehensive and integrated solutions. By expanding its Elekta Care offerings, Elekta can generate additional revenue and strengthen its relationships with healthcare providers. Timeline: Ongoing.

Market Cap of $2.37B reflects Elekta's position in the medical technology industry.
Gross Margin of 38.5% indicates the profitability of Elekta's products before operating expenses.
Debt-to-Equity Ratio of 90.91 suggests a leveraged capital structure, requiring careful monitoring.
Negative Profit Margin of -0.2% signals challenges in achieving overall profitability.
Beta of 1.09 indicates that the stock's price is slightly more volatile than the market.

EKTAF提供哪些产品和服务？

Develops and markets linear accelerators for radiation therapy.
Offers stereotactic radiosurgery systems, including the Gamma Knife.
Provides brachytherapy solutions for targeted radiation treatment.
Manufactures neurosurgery products, such as the Leksell Vantage Stereotactic System.
Offers oncology software suites for treatment planning and management.
Provides comprehensive support services, including training and maintenance.
Develops veterinary radiation therapy solutions.

EKTAF如何赚钱？

Sells linear accelerators and related radiation therapy equipment to hospitals and cancer centers.
Generates revenue from stereotactic radiosurgery systems and treatment planning software.
Offers brachytherapy solutions and associated services.
Provides maintenance and support services for its installed base of equipment.

Hospitals and cancer centers.
Neurosurgery clinics.
Veterinary clinics.
Research institutions.

Proprietary technology in radiation therapy and neurosurgery.
Established relationships with hospitals and cancer centers.
Comprehensive service offerings, including training and maintenance.
Strong brand reputation in the medical technology industry.

什么因素可能推动EKTAF股价上涨？

Ongoing: Expansion of Elekta Unity and Elekta Harmony product lines.
Ongoing: Growth in stereotactic radiosurgery and brachytherapy markets.
Ongoing: Increasing demand for veterinary radiation therapy solutions.
Ongoing: Expansion of Elekta Care support services.

EKTAF的主要风险是什么？

Potential: Competition from established players like Varian and Accuray.
Potential: Technological obsolescence.
Potential: Economic downturns affecting capital equipment spending.
Potential: Changes in healthcare regulations and reimbursement policies.
Ongoing: Negative profit margin and ROE.

EKTAF的核心优势是什么？

Comprehensive product portfolio in radiation therapy and neurosurgery.
Global presence with operations in multiple regions.
Strong brand reputation and established customer relationships.
Innovative technology, including Elekta Unity and Gamma Knife systems.

EKTAF的劣势是什么？

Negative profit margin and ROE.
High debt-to-equity ratio.
Dependence on capital equipment sales.
Exposure to regulatory and reimbursement risks.

EKTAF有哪些机遇？

Expansion of Elekta Unity and Elekta Harmony product lines.
Growth in stereotactic radiosurgery and brachytherapy markets.
Increasing demand for veterinary radiation therapy solutions.
Expansion of Elekta Care support services.

EKTAF面临哪些威胁？

Competition from established players like Varian and Accuray.
Technological obsolescence.
Economic downturns affecting capital equipment spending.
Changes in healthcare regulations and reimbursement policies.

EKTAF的竞争对手是谁？

Varian Medical Systems — Offers a broad range of radiation therapy and oncology solutions. — (VAR)
Accuray Incorporated — Specializes in robotic radiosurgery systems. — (ARAY)
Siemens Healthineers — Provides medical imaging and therapy solutions. — (SIEGY)

Key Metrics

MoonshotScore: 47/100

Company Profile

Headquarters: Stockholm, Sweden
Employees: 4,438

AI Insight

AI analysis pending for EKTAF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Elekta AB (publ) do?

Elekta AB (publ) is a medical technology company that provides clinical solutions for treating cancer and brain disorders. The company's core business revolves around developing, manufacturing, and marketing radiation therapy and neurosurgery equipment. Its product portfolio includes linear accelerators, stereotactic radiosurgery systems (like the Gamma Knife), brachytherapy solutions, and oncology software. Elekta's solutions are used in hospitals, cancer centers, and neurosurgery clinics worldwide, positioning the company as a key player in the global medical technology market focused on oncology and neurology treatments.

What do analysts say about EKTAF stock?

AI analysis is pending for EKTAF. Generally, analyst opinions on medical technology companies like Elekta AB (publ) consider factors such as revenue growth, profitability, and product innovation. Key valuation metrics include price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-EBITDA (EV/EBITDA). Growth considerations often focus on the adoption of new technologies, expansion into emerging markets, and the company's ability to maintain a competitive edge. However, without specific analyst reports, a detailed assessment is not possible.

What are the main risks for EKTAF?

Elekta AB (publ) faces several risks inherent to the medical technology industry. Competition from larger players like Varian and Accuray poses a constant threat. Technological obsolescence is a concern, requiring continuous investment in research and development. Economic downturns can impact capital equipment spending by hospitals and clinics, affecting sales. Changes in healthcare regulations and reimbursement policies can also affect the demand for Elekta's products. The company's negative profit margin and high debt-to-equity ratio add to the financial risks.